News
Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...
The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...
Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...
Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...
On today's Market Minute, Madison Mills takes a closer look at the top stories on Wall Street. UnitedHealth Group (UNH) stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results